Trial Profile

A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceritinib (Primary)
Indications Adenocarcinoma; Anaplastic large cell lymphoma; Colon cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Sarcoma; Soft tissue sarcoma; Solid tumours
Focus Proof of concept; Therapeutic Use
Acronyms ASCEND-10
Sponsors Novartis; Novartis Pharmaceuticals

31 May 2020 Results assessing ceritinib efficacy and safety in pts with advanced ALK+ non-lung solid tumors and hematological malignancies, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
17 Dec 2019 Status changed from completed to discontinued.
01 Dec 2018 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com